← Back to feedRead original →
VERIFIEDET Stocks·positive
Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook
AI Summary
- ·Gland Pharma's stock reached a 52-week high after strong March quarter and full-year financial results.
- ·The company's European subsidiary, Cenexi, is showing improved profitability.
- ·Future growth is expected from capacity expansions, new product launches, and an expanding contract development and manufacturing business.